alysis, and renal transplantation. The present study demonstrates that the apparent creatine kinase observed in the serum of such renal patients is an artifact, observed as a result of measuring creatine kinase isoenzymes by fluorescence.
Our Sera from normal persons and renal patients were scanned for endogeneous fluorescence with a spectrofluorometer (Model 204-A; Perkin-Elmer Corp., Norwalk, Conn. 06856) after dilution with 0.10 mol/liter NaCl.
Results
A typical CK isoenzyme pattern for renal patient sera is shown in Figure 1A . The pattern for the identical sample carried through the same procedure but without the reagents Both seradiluted 30-fold with water; excitation wavelength, 366 nm.
(substrate) to develop the CK bands is shown in Figure lB . Note thatthe fluorescent band in the renal serum remains at the CK I position. These fmdings were observed for more than 50 sera from renal patients. Analogous experiments in which the LDH fractionation method was used demonstratedthe renal sera giving rise to an additional band, anodic to LDH-
1.
In a preliminary effort to classify the spurious fluorescence, normal and renal patients' sera were subjected to routine protein electrophoresis. bumin fraction. In normal serum, a slight fluorescence in the albumin region was also observed. We did several studies to positively distinguish the material responsible for the fluorescence in the renal-disease sera from NADH. Figure 2 shows the fluorescence of a typical renal patient's serum compared to normal serum. The serum was diluted 30-fold with distilled water (pH approximately 7.0) and fluorescence emission spectra were recorded. Renalpatient samples exhibited an emission peak at 440 nm when excited at 366 nm. In another experiment, CK substrate was added to a renal patient's serum, and serial fluorescence spectra were recorded during 60 mm. The initial emission spectrum ( Figure 3A, 1 mm) essentially represents the endogenous fluorescence in the renal-patient serum. As the CK reaction proceeded, NADH was produced, altering the emission spectrum until, at 60 mm, the spectrum resembled that of NADH. When this reaction mixture (from Figure 3 , spectrum D) was further diluted (900-fold with distilled water), two emission maxima could be detected, at 449 and 425 nm (Figure 4) . Presumably, the 449-nm maximum was primarily due to NADH and the 425-nm shoulder was ascribable to the fluorescence of the renal-disease sera.
Renal-patients' sera were also treated with trichloroacetic acid (200 g/liter 3) The artifactual fluorescence coincides electrophoretically with albumin.
We suspect that the endogeneous fluorescent compound may be the result of vitamin B6 (pyridoxine) supplementation in the diet of renal patients.
As a class the vitamin B6 compounds (and metabolites) fluoresce in the same spectral region as the artifact. But McKenzie and Henderson concluded from in vivo and in vitro evidence that the vitamin B group was not responsible for the effect. However, addition of pyridoxine to normal serum produces a fluorescence spectrum different from the one produced when it is added to renal-patient's serum. Coursin and Brown have shown that 30 mg of pyridoxine HC1, given orally every 4 h for one day, did produce fluorescence in the blood (8). Further, pyridoxine is rapidly converted to pyridoxal phosphate in vivo, and there are marked differences in the extent to which each B6 compound is bound to albumin (9). Anderson also found that pyridoxine added to plasma did not bind to protein; however, pyridoxal phosphate was substantially bound along with some pyridoxal (9) . The actual clearance rate of B6 compounds from serum is not well-defined; however, Snell reported that only 15-20% of small amounts of [3Hpyridoxine administered to human subjects was recovered in the urine the first day, and that the remainder was excreted with a half life of 18-38 days (10) . We are grateful for the excellent technical assistance of Anneliesse
Kraemer.
